YIV-906 can also activate downstream cascades of TCR, which are the same cascades activated by most CAR constructs, and as predicted, YIV-906 can also promote NFAT activity of Jurkat cells expressing CAR-CD19 to enhance the killing power on tumor cells, independent of PD1-PD-L1 interaction. Here, CD19 is linked to neoplasm.